பல்கலைக்கழகம் ஆஃப் சான் டியாகோ பள்ளி மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

By Rebekah Gonzalez Feb 23, 2021 The University of San Diego School of Medicine has launched a first-in-human Phase I clinical trial to test the benefits and safety of gene therapy. They are now looking for participants. Researchers are using the trial to see if gene therapy can be used to deliver a key protein (brain-derived neurotrophic factor or BDNF) into the brains of those with Alzheimer s disease or Mild Cognitive Impairment, which often leads to dementia. We found that delivering BDNF to the part of the brain that is affected earliest in Alzheimer s disease - the entorhinal cortex and hippocampus - was able to reverse the loss of connections and to protect from ongoing cell degeneration, said

Mark tuszynskiSchool of medicineTranslational neuroscience instituteUniversity of san diego school medicineSan diego schoolMild cognitive impairmentSan diegoபள்ளி ஆஃப் மருந்துமொழிபெயர்ப்பு நரம்பியல் நிறுவனம்பல்கலைக்கழகம் ஆஃப் சான் டியாகோ பள்ளி மருந்துசான் டியாகோ பள்ளிலேசான அறிவாற்றல் குறைபாடுசான் டியாகோ